Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

David J. Woodhouse net worth and biography

David Woodhouse Biography and Net Worth

CEO of NGM Biopharmaceuticals

Dr. David J. Woodhouse brings to Surrozen’s board more than 18 years of experience throughout the biopharmaceutical industry, as a scientist and with expertise in strategy, finance, and capital development for growing biotechnology companies. He currently serves as the Chief Executive Officer and a director at NGM Biopharmaceuticals. He previously served as NGM’s Chief Financial Officer for over three years. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a Managing Director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.

How old is David J. Woodhouse?: Dr. Woodhouse is currently 53 years old. There are 3 older executives and no younger executives at NGM Biopharmaceuticals. The oldest executive at NGM Biopharmaceuticals is Mr. William J. Rieflin J.D., Executive Chairman of the Board of Directors, who is 64 years old. Learn More on David J. Woodhouse's age.
How do I contact David J. Woodhouse?: The corporate mailing address for Dr. Woodhouse and other NGM Biopharmaceuticals executives is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. NGM Biopharmaceuticals can also be reached via phone at (650) 243-5555 and via email at [email protected]. Learn More on David J. Woodhouse's contact information.
Has David J. Woodhouse been buying or selling shares of NGM Biopharmaceuticals?: David J. Woodhouse has not been actively trading shares of NGM Biopharmaceuticals within the last three months. Most recently, David J. Woodhouse sold 15,000 shares of the business's stock in a transaction on Thursday, November 18th. The shares were sold at an average price of $20.02, for a transaction totalling $300,300.00. Learn More on David J. Woodhouse's trading history.
Who are NGM Biopharmaceuticals' active insiders?: NGM Biopharmaceuticals' insider roster includes Jin-Long Chen (Insider), Hsiao Lieu (SVP), and David Woodhouse (CEO). Learn More on NGM Biopharmaceuticals' active insiders.

David J. Woodhouse Insider Trading History at NGM Biopharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/18/2021	Sell	15,000	$20.02	$300,300.00

David J. Woodhouse Buying and Selling Activity at NGM Biopharmaceuticals

NGM Biopharmaceuticals Company Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.54

$1.54

$1.57

50 Day Range

MA: $1.57

$1.52

$1.92

2 Week Range

Now: $1.54

$0.60

$4.69

Volume

2,390,800 shs

Average Volume

1,467,160 shs

Market Capitalization

$128.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27